CL2011001445A1 - Compuesto 3-(4-cloro-2-fluorobencil)-2-metil-n-(5-metil-1h-pirazol-3-il)-8-(morfolinometil)imidazo[1,2-b]piridazin-6-amina; composicion farmaceutica; y uso en el tratamiento de trastornos mieloproliferantes cronicos y en el tratamiento de glioblastoma, cancer de amama, mieloma multiple, cancer de prostata y leucemias - Google Patents

Compuesto 3-(4-cloro-2-fluorobencil)-2-metil-n-(5-metil-1h-pirazol-3-il)-8-(morfolinometil)imidazo[1,2-b]piridazin-6-amina; composicion farmaceutica; y uso en el tratamiento de trastornos mieloproliferantes cronicos y en el tratamiento de glioblastoma, cancer de amama, mieloma multiple, cancer de prostata y leucemias

Info

Publication number
CL2011001445A1
CL2011001445A1 CL2011001445A CL2011001445A CL2011001445A1 CL 2011001445 A1 CL2011001445 A1 CL 2011001445A1 CL 2011001445 A CL2011001445 A CL 2011001445A CL 2011001445 A CL2011001445 A CL 2011001445A CL 2011001445 A1 CL2011001445 A1 CL 2011001445A1
Authority
CL
Chile
Prior art keywords
methyl
treatment
morpholinomethyl
fluorobenzyl
imidazo
Prior art date
Application number
CL2011001445A
Other languages
English (en)
Inventor
Timothy Paul Burkholder
Joshua Ryan Clayton
Liandong Ma
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41630090&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011001445(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2011001445A1 publication Critical patent/CL2011001445A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuesto 3-(4-cloro-2-fluorobencil)-2-metil-n-(5-metil-1h-pirazol-3-il)-8-(morfolinometil)imidazo[1,2-b]piridazin-6-amina; composición farmacéutica; y uso en el tratamiento de trastornos mieloproliferantes crónicos y en el tratamiento de glioblastoma, cáncer de mama, mieloma múltiple, cáncer de próstata y leucemias.
CL2011001445A 2008-12-16 2011-06-15 Compuesto 3-(4-cloro-2-fluorobencil)-2-metil-n-(5-metil-1h-pirazol-3-il)-8-(morfolinometil)imidazo[1,2-b]piridazin-6-amina; composicion farmaceutica; y uso en el tratamiento de trastornos mieloproliferantes cronicos y en el tratamiento de glioblastoma, cancer de amama, mieloma multiple, cancer de prostata y leucemias CL2011001445A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12285408P 2008-12-16 2008-12-16

Publications (1)

Publication Number Publication Date
CL2011001445A1 true CL2011001445A1 (es) 2011-11-11

Family

ID=41630090

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011001445A CL2011001445A1 (es) 2008-12-16 2011-06-15 Compuesto 3-(4-cloro-2-fluorobencil)-2-metil-n-(5-metil-1h-pirazol-3-il)-8-(morfolinometil)imidazo[1,2-b]piridazin-6-amina; composicion farmaceutica; y uso en el tratamiento de trastornos mieloproliferantes cronicos y en el tratamiento de glioblastoma, cancer de amama, mieloma multiple, cancer de prostata y leucemias

Country Status (39)

Country Link
US (2) US20100286139A1 (es)
EP (1) EP2379557B1 (es)
JP (1) JP5509217B2 (es)
KR (1) KR101300458B1 (es)
CN (1) CN102232075B (es)
AR (1) AR074240A1 (es)
AU (1) AU2009330503B2 (es)
BR (1) BRPI0923048A2 (es)
CA (1) CA2744714C (es)
CL (1) CL2011001445A1 (es)
CO (1) CO6331442A2 (es)
CR (1) CR20110341A (es)
CY (1) CY1113637T1 (es)
DK (1) DK2379557T3 (es)
DO (1) DOP2011000190A (es)
EA (1) EA019554B1 (es)
EC (1) ECSP11011132A (es)
ES (1) ES2396617T3 (es)
HK (1) HK1160109A1 (es)
HN (1) HN2011001697A (es)
HR (1) HRP20120918T1 (es)
IL (1) IL213065A0 (es)
JO (1) JO2833B1 (es)
MA (1) MA32900B1 (es)
MX (1) MX2011006441A (es)
MY (1) MY158691A (es)
NZ (1) NZ592641A (es)
PA (1) PA8851101A1 (es)
PE (1) PE20110549A1 (es)
PL (1) PL2379557T3 (es)
PT (1) PT2379557E (es)
SG (1) SG172202A1 (es)
SI (1) SI2379557T1 (es)
SV (1) SV2011003949A (es)
TN (1) TN2011000292A1 (es)
TW (1) TWI440640B (es)
UA (1) UA104743C2 (es)
WO (1) WO2010074947A1 (es)
ZA (1) ZA201103942B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2435646A (en) * 2006-03-01 2007-09-05 Spin Tec Engineering Gmbh Apparatus and method of extraction of an arthropod gland
US8105633B2 (en) * 2006-03-01 2012-01-31 Spintec Engineering Gmbh Method and apparatus for extraction of arthropod gland
US20110121485A1 (en) * 2006-10-30 2011-05-26 Spintec Engineering Gmbh Method and apparatus for the manufacture of a fiber
CN103619873A (zh) * 2011-03-07 2014-03-05 泰莱托恩基金会 Tfeb变体及其应用
WO2012172069A1 (en) * 2011-06-15 2012-12-20 Life And Brain Gmbh Glioblastoma inhibiting compounds and their use
SG11201408679XA (en) 2012-06-26 2015-01-29 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
PL400213A1 (pl) 2012-08-01 2014-02-03 Celon Pharma Spólka Z Ograniczona Odpowiedzialnoscia Pochodne imidazo[1,2-b]pirydazyno-6-aminy jako inhibitory kinazy JAK-2
TW201618773A (zh) 2014-08-11 2016-06-01 艾森塔製藥公司 Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、及／或ｃｄｋ４／６抑制劑的治療組合物
WO2016024228A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor
LT3179991T (lt) 2014-08-11 2021-11-10 Acerta Pharma B.V. Terapiniai btk inhibitoriaus ir bcl-2 inhibitoriaus deriniai
CN110191887B (zh) * 2016-11-17 2022-02-18 百时美施贵宝公司 IL-12、IL-23和/或IFN-α的咪唑并哒嗪调节剂
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
EP3610264A1 (en) 2017-04-13 2020-02-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
CN110305140B (zh) 2019-07-30 2020-08-04 上海勋和医药科技有限公司 二氢吡咯并嘧啶类选择性jak2抑制剂

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6989385B2 (en) 2000-12-21 2006-01-24 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
JP2003137785A (ja) * 2001-08-23 2003-05-14 Takeda Chem Ind Ltd Ｊｎｋ活性化阻害剤
IL161784A0 (en) 2001-12-21 2005-11-20 Anormed Inc Chemokine receptor binding heterocyclic compounds with enhanced efficacy
PL1853588T3 (pl) 2005-02-16 2008-11-28 Astrazeneca Ab Związki chemiczne
DE602006015431D1 (de) 2005-02-16 2010-08-26 Astrazeneca Ab Chemische verbindungen
ATE527253T1 (de) * 2005-07-01 2011-10-15 Irm Llc Pyrimidin-substituierte benzimidazolderivate als proteinkinasehemmer
GB0515026D0 (en) * 2005-07-21 2005-08-31 Novartis Ag Organic compounds
WO2007044426A2 (en) 2005-10-06 2007-04-19 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
AR056206A1 (es) * 2005-10-06 2007-09-26 Schering Corp Pirazolpirimidinas como inhibidores de protein quinasas
AU2006320580B2 (en) 2005-11-30 2011-06-23 Vertex Pharmaceuticals Incorporated Inhibitors of c-Met and uses thereof
US7989459B2 (en) * 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
WO2008030579A2 (en) 2006-09-07 2008-03-13 Biogen Idec Ma Inc. Irak modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder
KR20090075714A (ko) * 2006-10-30 2009-07-08 노파르티스 아게 소염제로서의 헤테로시클릭 화합물
WO2008129255A1 (en) * 2007-04-18 2008-10-30 Astrazeneca Ab 5-aminopyrazol-3-yl-3h-imidazo [4,5-b] pyridine derivatives and their use for the treatment of cancer
WO2008143674A1 (en) 2007-05-23 2008-11-27 Pharmacopeia, Inc. Purinones and 1h-imidazopyridinones as pkc-theta inhibitors
WO2009062059A2 (en) 2007-11-08 2009-05-14 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors

Also Published As

Publication number Publication date
US20100152181A1 (en) 2010-06-17
TW201024301A (en) 2010-07-01
ZA201103942B (en) 2012-08-29
US7897600B2 (en) 2011-03-01
DK2379557T3 (da) 2012-12-17
UA104743C2 (ru) 2014-03-11
HN2011001697A (es) 2013-11-26
KR20110084993A (ko) 2011-07-26
SI2379557T1 (sl) 2013-02-28
PT2379557E (pt) 2013-01-14
PE20110549A1 (es) 2011-08-04
DOP2011000190A (es) 2011-07-31
PA8851101A1 (es) 2010-07-27
WO2010074947A1 (en) 2010-07-01
TWI440640B (zh) 2014-06-11
CO6331442A2 (es) 2011-10-20
MY158691A (en) 2016-10-31
AR074240A1 (es) 2011-01-05
BRPI0923048A2 (pt) 2018-09-25
CN102232075B (zh) 2013-12-11
ES2396617T3 (es) 2013-02-22
SG172202A1 (en) 2011-07-28
IL213065A0 (en) 2011-07-31
CR20110341A (es) 2011-07-13
JP2012512158A (ja) 2012-05-31
PL2379557T3 (pl) 2013-03-29
ECSP11011132A (es) 2011-07-29
TN2011000292A1 (en) 2012-12-17
EP2379557A1 (en) 2011-10-26
EA019554B1 (ru) 2014-04-30
EP2379557B1 (en) 2012-10-31
MA32900B1 (fr) 2011-12-01
SV2011003949A (es) 2011-07-21
CN102232075A (zh) 2011-11-02
JO2833B1 (en) 2014-09-15
CA2744714C (en) 2013-06-25
AU2009330503B2 (en) 2012-06-07
EA201170831A1 (ru) 2011-12-30
MX2011006441A (es) 2011-07-19
AU2009330503A1 (en) 2010-07-01
US20100286139A1 (en) 2010-11-11
JP5509217B2 (ja) 2014-06-04
CA2744714A1 (en) 2010-07-01
HRP20120918T1 (hr) 2012-12-31
HK1160109A1 (en) 2012-08-10
KR101300458B1 (ko) 2013-08-30
NZ592641A (en) 2013-01-25
CY1113637T1 (el) 2016-06-22

Similar Documents

Publication Publication Date Title
CL2011001445A1 (es) Compuesto 3-(4-cloro-2-fluorobencil)-2-metil-n-(5-metil-1h-pirazol-3-il)-8-(morfolinometil)imidazo[1,2-b]piridazin-6-amina; composicion farmaceutica; y uso en el tratamiento de trastornos mieloproliferantes cronicos y en el tratamiento de glioblastoma, cancer de amama, mieloma multiple, cancer de prostata y leucemias
CL2011001863A1 (es) Compuestos derivados de fenilaminopirimidinas, inhibidores de quinasa del linfoma anaplastico; composicion farmaceutica; combinacion farmacologica; y su uso en el tratamiento de trastornos proliferativos tales como linfoma, osteosarcoma, melanoma o tumor de mama, renal y de prostata, entre otros (divisional solicitud 3552-07).
PH12020552065A1 (en) Ibrutinib combination therapy
CL2008001745A1 (es) Compuestos derivados de imidazo[1,2-a]pirazina; composición farmacéutica; y uso de los compuestos como inhibidores de la proteína quinasa en el tratamiento del cáncer.
CL2008003846A1 (es) Uso de compuestos derivados de 1,2,4-triazolo condensado con heterociclos, los cuales actuan como ligados del receptor de androgeno (ar); compuestos; proceso de preparacion; composicion farmaceutica y el uso de dichos compuestos para el tratamiento del cancer de prostata.
CL2007002062A1 (es) Compuestos derivado de [1,2,4]triazolo[4,3-a]piridina, inhibidores de quinasa; composicion farmaceutica; y su uso en el tratamiento del cancer.
DOP2009000196A (es) Inhibidores de la actividad de akt
MX370814B (es) Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
CL2012000772A1 (es) Compuestos derivados de hetorociclos carboxamidicos sustituidos, antagonista ar; composición farmacéutica que los comprende; y uso en el tratamiento del cáncer de próstata.
CL2008002097A1 (es) Compuestos derivados de heterociclos condensados sustituidos, inhibidores de cinasa de fosfatidil-inositol-3; composicion farmaceutica; y uso en el tratamiento del cancer.
ECSP088425A (es) INHIBIDORES DE LA ACTIVIDAD Akt
CL2008001540A1 (es) Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer.
EA201490194A1 (ru) Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака
CL2011000116A1 (es) Compuestos derivados de imidazo[1,2-a]piridina; procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; y uso en el tratamiento del cancer.
CL2011002956A1 (es) Compuestos derivados de pirrolo[2,3-d]pirimidina, inhibidores de la quinasa janus (jak1); composicion farmaceutica; y uso para el tratamiento de una enfermedad autoinmune, cancer, trastorno mieloproliferativo, una enfermedad inflamatoria o rechazo de trasplante de organos.
CL2008001025A1 (es) Compuestos derivados de pirimido[5,4-d]pirimidina-2,4,6,8-tetraona; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como trastorno metabolico, dislipidemia y cancer.
CL2013002177A1 (es) Compuestos derivados de 9h-purinas y 7h-pirrolo[2,3-d]-pirimidinas sustituidas, inhibidores de la pi3k de clase i y/o mtor; su composicon farmaceutica; su combinacion farmaceutica; y su uso en el tratamiento o la prevencion del cancer o trastornos neurodegenerativos.
PE20141197A1 (es) INHIBIDORES DE mTOR CINASA PARA INDICADORES DE ONCOLOGIA Y ENFERMEDADES ASOCIADAS CON LA TRAYECTORIA mTOR/PI3K/AKT
AR057941A1 (es) Agentes terapeuticos para el cancer de prostata
CL2011000119A1 (es) Compuestos derivados de triazolo[4,3-a]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
UY29439A1 (es) Nuevos compuestos
CL2011001152A1 (es) Compuesto cristalino 6-((s)-1-(6-(1-metil-1h-pirazol-4-il)-[1,2,4]triazolo[3,4-b][1,3,4]tiadiazol-3-il)etil)quinolina, inhibidor de la proteina kinasa c-met; composicion farmaceutica; y metodo para tratar o disminuir la gravedad de un trastorno proliferativo tal como cancer metastasico de colon, mama y hepatico, entre otros.
EA200800223A1 (ru) ПРОИЗВОДНЫЕ ПИРИДО[2,3-d]ПИРИМИДИНА, ИХ ПОЛУЧЕНИЕ, ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ
BR112013033544A2 (pt) dosagem e administração de anticorpos anti-erbb3 em combinação com paclitaxel para tratamento de cânceres ginecológicos
CL2011002812A1 (es) Compuestos derivados de [1,2,4]triazolo[4,3-b]piridazinas; proceso de preparacion; y uso en el tratamiento del cancer a la prostata.